Skip to main content
. 2014 Feb 5;34(4):553–563. doi: 10.1038/jcbfm.2014.18

Table 1. Arteriogenic interventions in experimental stroke research.

Treatment Author Species Ischemia model Assessment techniques End points
GM-CSF Buschmann et al119 Sprague-Dawley rats Brain hypoperfusion: left common carotid and bilateral vertebral artery occlusion. Angiogram using latex perfusion and histochemical analysis for monocytes (CD 68) and proliferation marker, Ki-67 Posterior cerebral artery arteriogenesis together with increased cell proliferation and monocyte infiltration
Niacin Chen et al120 Wistar rats tMCAO for 2 hours Latex perfusion and double histochemical staining for cell proliferation marker, BrdU and VSMCs (α-SMA) Increased diameter of the Circle of Willis arteries together with increased arterial diameter and BrdU-positive VSMCs in the ischemic border zone
Simvastatin Zacharek et al121 Wistar rats tMCAO for 2 hours Double histochemical staining for cell proliferation marker, BrdU and VSMCs (α-SMA) Increased arterial density, diameter, and perimeter in the ischemic border zone
G-CSF Sugiyama et al122 C57BL/6 mice Left common carotid artery occlusion Angiogram using latex perfusion and histochemical analysis for monocytes (Mac-2) Leptomeningeal collateral growth and monocyte infiltration in the dorsal surface of the brain
Tocotrienol (Vitamin E) Rink et al123 Mongrel canines tMCAO for 1 hour Digital subtraction angiography Improved leptomeningeal collateral circulation
Simvastatin and Human umblical cord blood cells combination Cui et al124 Wistar rats tMCAO for 2 hours Double immunofluorescent staining for BrdU (marker of proliferating cells) and α-SMA (VSMCs marker) The diameter and the density of α-SMA arteries were significantly increased in the ipsilateral hemisphere. In addition, the percentage of BrdU-VSMC in the artery walls was also significantly increased at 14 days after stroke
GW3965 (synthetic liver X receptor agonist) Cui et al125 C57BL/6J mice tMCAO for 2.5 hours Double immunofluorescent staining for BrdU (marker of proliferating cells) and α-SMA (VSMCs marker) GW3965 treatment significantly increased the arterial density and the diameter of α-SMA arteries and the percentage of BrdU-SMCs in arteries

CD 68, cluster of differentiation 68; GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; BrdU, bromodeoxyuridine; α-SMA, α-smooth muscle actin; tMCAO, temporary middle cerebral artery occlusion; SMC, smooth muscle cell; VSMCs, vascular SMCs.